A product used for the treatment of coccidiosis in pigs, horses and dairy cattle has now been licensed for use in beef calves.
The only toltrazuril-licensed treatment for coccidiosis in bull beef and suckler calves in the UK, Baycox® Multi enables beef producers to treat and control one of the most common causes of scour.
“The single-dose treatment is already available for use in dairy calves, and has been proven in trials as an effective preventive treatment in beef calves,” says Fraser Claughton. Bayer UK/IE commercial manager.
“Preventive control with Baycox Multi resulted in Chianina beef calves averaging 11kg heavier at 40 weeks post-treatment compared to those given diclazuril.”
Baycox Multi has also been proven to significantly reduce the shedding of eggs in the animal’s faeces, helping to limit the spread of disease.
“Coccidiosis causes damage to the gut wall which can lead to long-term problems with nutrient absorption and susceptibility to future infection. Treatment with Baycox® Multi prevents this,” he says.
Beef producers are advised to watch for symptoms of coccidiosis most prevalent in calves aged three to 12 weeks of age, and can occur throughout the calf’s first year.
“Recognising subclinical symptoms of coccidiosis such as decreased appetite, weight loss, a dull coat and loose faeces is vital. The first signs of an outbreak should be investigated immediately through your vet, and once you know you are treating coccidiosis, Baycox Multi is an excellent choice to treat all stages of the pathogen and is effective for longer than other products,” he explains.
Treated cattle not only experience benefits against existing infection, but also go on to develop a normal or enhanced immune response to infection later in life, benefiting both animal performance and welfare.
The anti-coccidial drug is administered orally and suitable for use in beef calves under 150kg.
For more information on Baycox Multi, contact your local Bayer territory manager.